GILD Stock Forecast: Gilead Sciences, Inc. Price Predictions for 2026-2027
The 28 Wall Street analysts covering Gilead Sciences, Inc. hold a median 12-month price target of $178 — +6.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 89 of 100 as at 21 Nov 2026 — inside the top quartile. Here, the model and the Street point the same way.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Gilead Sciences, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Volatility (100): The share price has been relatively steady.
Issuance (51): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
GILD stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on GILD, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +6.9% from it.
Of the 20 most recent actions, 17 moved their price target up and 1 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 16 Nov 2026 | Barclays | Maintains | Equal-Weight | $145 → $160 |
| 31 Oct 2026 | UBS | Maintains | Buy | — |
| 30 Oct 2026 | Cantor Fitzgerald | Maintains | Overweight | $155 → $175 |
| 30 Oct 2026 | Citigroup | Maintains | Buy | $165 → $188 |
| 30 Oct 2026 | JP Morgan | Maintains | Overweight | $170 → $190 |
| 30 Oct 2026 | Morgan Stanley | Maintains | Overweight | $163 → $183 |
| 30 Oct 2026 | Needham | Maintains | Buy | $170 → $200 |
| 30 Oct 2026 | RBC Capital | Maintains | Sector Perform | $126 → $131 |
| 30 Oct 2026 | Scotiabank | Maintains | Sector Outperform | $177 → $200 |
| 30 Oct 2026 | TD Cowen | Maintains | Buy | $160 → $175 |
| 30 Oct 2026 | Truist Securities | Maintains | Buy | $158 → $181 |
| 30 Oct 2026 | UBS | Maintains | Buy | $175 → $195 |
| 30 Oct 2026 | Wells Fargo | Maintains | Overweight | $165 → $190 |
| 20 Oct 2026 | B of A Securities | Maintains | Buy | $168 → $172 |
| 8 Oct 2026 | Cantor Fitzgerald | Reiterates | Overweight | $155 |
| 8 Oct 2026 | RBC Capital | Maintains | Sector Perform | $123 → $126 |
| 7 Oct 2026 | JP Morgan | Maintains | Overweight | $160 → $170 |
| 7 Oct 2026 | Morgan Stanley | Maintains | Overweight | $165 → $163 |
| 7 Oct 2026 | Truist Securities | Maintains | Buy | $150 → $158 |
| 10 Sept 2026 | HSBC | Maintains | Buy | $155 → $175 |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for GILD.
This page is one stock. Monday covers all of them.
GILD appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
GILD vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, Gilead Sciences, Inc. returned +36.4% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
GILD analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- 6.8×
- Price / book
- 16.1×
- EV / EBITDA
- 15.3×
Cheaper than 16% of US stocks
Cheaper than 4% of US stocks
Cheaper than 32% of US stocks
- Revenue growth (YoY)
- 6.8%
- Earnings growth (YoY)
- —
- Gross margin
- 79.8%
- Operating margin
- 38.2%
- Net margin
- −12.5%
Higher than 46% of US stocks
Higher than 90% of US stocks
Higher than 92% of US stocks
Higher than 19% of US stocks
- Return on equity
- −22.4%
- Return on assets
- 13.5%
- Dividend yield
- 1.9%
Higher than 31% of US stocks
Higher than 96% of US stocks
Higher than 41% of US dividend payers
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Gilead Sciences, Inc. has a market value of $206.6B and an enterprise value of $224.7B.
Revenue in the twelve months to 30 June 2026: $30.5B. The latest quarter grew 10.2% year on year.
Net income over the same four quarters: −$3.2B, a −10.6% net margin.
Diluted earnings per share, trailing twelve months: −$2.67.
Free cash flow in the twelve months to 30 June 2026: $12.9B.
Gilead Sciences, Inc. spent $1.4B on share buybacks and $4.1B on dividends in the twelve months to 30 June 2026.
forward P/E: 16.6× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 1.94%.
Gilead Sciences, Inc. employs 17,000 people — $1.8M of revenue per employee.
Data provided by Twelve Data
GILD and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at GILD’s peer groups, ranked by the model: healthcare stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Gilead Sciences, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about GILD
What is the GILD stock price forecast for 2026-2027?
The 28 Wall Street analysts covering Gilead Sciences, Inc. have a median 12-month price target of $178, with estimates ranging from $131 to $200. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is GILD stock a buy right now?
Of the 28 analysts covering Gilead Sciences, Inc., 22 rate it a Buy, 5 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Gilead Sciences, Inc. 89 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank GILD?
As at 21 Nov 2026, Gilead Sciences, Inc. ranks 89 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Volatility (100 of 100).
Will GILD stock go up?
No one can know that. What the data says: the median 12-month target from 28 analysts implies +6.9% from the last close, and Ticker Nerd's factor model ranks Gilead Sciences, Inc. 89 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the GILD stock forecast for 2030?
No analyst covering Gilead Sciences, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for GILD are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $131 to $200 over the next 12 months.
How has GILD stock performed over the past year?
Gilead Sciences, Inc. returned +36.4% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Gilead Sciences, Inc. do?
Gilead Sciences Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing medicines for serious and life-threatening diseases. Its current business centers on virology, oncology, and inflammation, with a particularly strong position in HIV treatment and a broader portfolio that also addresses liver disease, respiratory conditions, cardiovascular disease, and cancer.
About Gilead Sciences, Inc.
Gilead Sciences Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing medicines for serious and life-threatening diseases. Its current business centers on virology, oncology, and inflammation, with a particularly strong position in HIV treatment and a broader portfolio that also addresses liver disease, respiratory conditions, cardiovascular disease, and cancer. Gilead Sciences Inc. markets established therapies and newer medicines aimed at unmet medical needs, supported by ongoing research and clinical programs across multiple therapeutic areas. The company also works with partnerships and access programs that help expand the reach of its medicines in global markets. Headquartered in Foster City, California, Gilead Sciences Inc. operates as an important healthcare innovator with products and services that serve patients, clinicians, and health systems worldwide.
CEO Mr. Daniel Patrick O'Day · 17,000 employees · United States · https://www.gilead.com